Reata Reports Positive Top-Line Data

Reata Pharma (RETA), a clinical-stage biopharmaceutical company, reported pre-market Thursday positive top-line data from the mid-stage Lariat trial evaluating bardoxolone methyl for the treatment of pulmonary hypertension (PH) in patients with interstitial lung disease (ILD).

Results from the trial showed significant improvements in the primary endpoint of the trial, which was change from baseline in the six-minute walk distance week 16, and no safety signals were identified.

“We are encouraged by these initial results, especially those in IPF patients, and they support our ongoing efforts in pulmonary hypertension,” chief medical officer Colin Meyer said in a statement. “Once we complete our other ongoing Phase 2 trials, we will evaluate all available data from our mid-stage trials to determine prioritization and timing for this and our other programs.”

Leave a Comment